MENLO PARK, Calif., June 14, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, presented results of a three (3) arm preclinical study comparing BPX-01 topical hydrophilic formulation of minocycline, lipophilic minocycline formulation and oral minocyline.
The findings were presented in a poster entitled "Effectiveness and Safety of a Topical Hydrophilic Minocycline Compared to a Topical Lipophilic Minocycline." The poster was presented by BioPharmX Senior Director of Preclinical Drug Development, Usha Nagavarapu, Ph.D., at The Westin Copely Place in Boston, MA on Tuesday. More information and details of the poster can be found on the company's website.
"The study reinforces the efficient penetration and lack of systemic exposure that the hydrophilic BPX-01 may offer over both lipophilic minocycline formulations and oral minocycline." said Kin F. Chan, Ph.D., executive vice president of research and technology at BioPharmX. "BPX-01 delivered minocycline to the pilosebaceous unit where acne resides and could not be traced in plasma."
BioPharmX recently completed a phase 2b clinical study. The data showed BPX-01 2% reduced the number of inflammatory lesions in acne patients by 59% (versus 44% in vehicle) with no serious drug-related side effects, and suggested it may also lessen the severity of lesions. The company plans to begin its phase 3 research later this year.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting up to 50 million Americans. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the effectiveness of BPX-01 and the successful advancement of the company's product candidate. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biopharmx-invited-to-present-at-world-preclinical-congress-300473676.html
SOURCE BioPharmX Corporation